Home Add to Favorite Contact Submit  
           16 May, 2021

Category:  Press » Politics & Government


FDA Approves the First Once-a-Day Three-Drug Combination Tablet for Treatment of HIV-1

         Views: 1610
2006-07-13 04:33:13     
Food and Drug Administration (FDA)

Atripla is a Landmark Achievement of Three Cooperating Companies The Food and Drug Administration (FDA) today announced approval of Atripla Tablets, a fixed-dose combination of three widely-used antiretroviral drugs, in a single tablet taken once a day, alone or in combination with other antiretroviral products for the treatment of HIV-1 infection in adults. Atripla, the first one-pill, once-a-day product to treat HIV/AIDS, combines the active ingredients of Sustiva (efavirenz), Emtriva (emtricitabine) and Viread (tenofovir disoproxil fumarate). Bristol-Myers Squibb and Gilead Sciences have formed a joint venture to commercialize Atripla in the United States. The collaboration is the first of its kind in the field of HIV/AIDS. In certain territories, Merck holds the rights to efavirenz. All three companies will work together to ensure the product is available to patients and physicians. Atripla will be available for use in the United States as a new product approved under a new drug application (NDA). This would allow the drug to be considered for purchase for use in 15 other countries included under the President’s Emergency Plan for AIDS Relief (PEPFAR). HIV-1 affects people worldwide. Atripla was approved in under three months under FDA’s fast track program. The manufacturer plans to make the drug available for purchase in the United States within 96 hours. "This key breakthrough will help in our battle against HIV/AIDS -- not only in the U.S. but in other countries through the PEPFAR program. I commend those involved for working together to place this lifesaving drug on the fast track so it will be available more quickly to those who need it," said Mike Leavitt, Secretary of Health and Human Services. The approval of Atripla comes as the result of an expedited review process outlined in a guidance by the FDA in May 2004. With today’s approval, FDA will have approved seven co-packaged or fixed-dose combination products since the guidance was issued. For more information about the FDA’s Expedited Review Process for HIV/AIDS Drugs, "Today’s approval is a significant example of drug developers and FDA clearing the way to quickly deliver quality, life-saving HIV/AIDS drugs to people who desperately need them in the United States and abroad," said Andrew C. von Eschenbach, MD, Acting Commissioner of Food and Drugs. "Fixed dose combination products are an important tool in improving the quality of health care in developing nations. The approval of Atripla is a significant step forward in our commitment to providing medical care as effectively and efficiently as possible." "The approval of Atripla simplifies the treatment regimen for HIV-1 infected adults, and will potentially improve the ability of patients to adhere to treatment resulting in long-term effective control of HIV-1. This offers a particularly important advantage for patients in many countries that are most affected by the AIDS epidemic and will also have a major impact in the U.S.," said Dr. Andrew C. von Eschenbach, the Acting Commissioner of Food and Drugs. "Atripla illustrates the outstanding achievements that are attainable when several pharmaceutical companies cooperate with our agency toward a common public health goal. I congratulate the three firms behind this unprecedented success -- and our reviewers, who worked with them every step of the way, on a job extremely well done." "This new product offers a welcome option for prescribers who follow the recommended initiation of HIV-1 treatment with at least three highly active antiretroviral drugs, a regimen that has the potential to significantly improve the condition of many patients, and help them adhere to their regimen to help minimize the development of viral resistance," said Dr. Steven Galson, Director of FDA’s Center for Drug Evaluation and Research. "Because all three components of Atripla have been in use for some time, their characteristics and effects are well known." FDA approved Sustiva in 1998, Viread in 2001 and Emtriva in 2003. In addition, the safety and effectiveness of the combination of these three drugs were shown in a 48 week clinical study with 244 HIV-1 infected adults receiving the drugs contained in Atripla. In this trial, 80 percent of the participants achieved a marked reduction of the human immunodeficiency virus and a substantial increase in the number of healthy CD4 cells -- cells that fight against infection. The labeling of Atripla includes a boxed warning that the drug’s use can cause lactic acidosis (buildup of lactic acid in the blood). In patients with chronic Hepatitis B infection, the discontinuation of the treatment with Atripla (which is not approved for this use) can result in severe flare-ups of Hepatitis B infection. Other potential serious adverse events reported for the use of Atripla’s ingredients include serious liver toxicity, renal impairment and severe depression. The most common adverse events experienced by participants in the combination trial included headache, dizziness, abdominal pain, nausea, vomiting and rash. There are more than a million people living with HIV and AIDS in the United States today and 40,000 new cases are reported each year. Currently, there are 28 FDA approved products in the United States used in the treatment of HIV infection. FDA has played a strong role in addressing treatment and prevention from the beginning of the AIDS epidemic and has made significant contributions to the development of potent antiviral drugs that have dramatically helped people with HIV and AIDS live longer and healthier lives. Also within the last two years, FDA has approved more than 20 treatments to be used as part of President’s Emergency Plan for AIDS Relief program, a $15 billion dollar initiative, which President Bush first announced in his 2003 State of the Union Address, to fight the international HIV/AIDS pandemic. PEPFAR is designed to prevent seven million new HIV infections, treat at least two million HIV-infected people, and care for ten million HIV-affected individuals, AIDS orphans and vulnerable children worldwide.

Specialized in: Fda - Drug Combination - Hiv-1
URL: http://www.fda.gov
Print press release      Bookmark this page
Related Press releases 
Winning Freedom Super PAC Formed to Back Newt Gingrich Presidential Bid (Popularity: ): AUSTIN, Texas, March 2, 2012 -- Brandon Todd, a prominent Texas entrepreneur and Tea Party Leader, today announced the formation of a new Super PAC (Political Action Committee) to support the Presidential bid of former Speaker of the House Newt Gingrich.Mr. Todd stated: "This is the most important election of our lifetime. It will have a profound impact on man's quest to rule itself and live in this world as ...
Pelosi Announces Run For House Democratic Leader (Popularity: ): Speaker Nancy Pelosi released the following letter to her Democratic colleagues this afternoon announcing that she will run to become House Democratic Leader in the next Congress.Excerpt from her letter to Democratic colleagues:"Our work is far from finished. As a result of Tuesday's election, the role of Democrats in the 112th Congress will change, but our commitment to serving the American people will not. We have no intention of allowing ...
Saudi Arabia Emphasizes Limited Time Left for Peaceful Two-State Solution (Popularity: ): The official statement of the Kingdom of Saudi Arabia at the General Debate of the Sixty-Fifth Session of the United Nations was distributed on September 25. The statement, issued by Saudi Foreign Minister Prince Saud Al-Faisal called for continued humanitarian aid to Pakistan following the devastating floods. In addition, it spoke to a number of security issues, including Saudi Arabia's aggressive counterterrorism program and the need for a nuclear-free Middle ...
Toys"R"Us® to Hire 45,000 Seasonal Employees Nationwide This Christmas to Meet Shoppers' Needs (Popularity: ): Toys"R"Us® today announced plans to hire approximately 45,000 seasonal employees to staff its Toys"R"Us and Toys"R"Us Express pop-up stores in the U.S. this holiday season, essentially doubling its domestic workforce. This number is greater than the total workforce the company hired during each of the last three holiday shopping seasons due to the addition of 600 new Toys"R"Us Express stores. In previous holiday seasons, the company has hired approximately 35,000 ...
National Political Study: Social Networks Supercharge Political Campaigns (Popularity: ): Results of a new national study among 1,581 Americans revealed that voters are becoming more interested in getting involved with campaigns, and those that are most engaged are much more likely to vote. Three out-of-five of Americans who consider themselves somewhat politically active are members of a social network, and 70% reported that they expect to vote in November. Four out-of-five potential voters expect candidates to have a website, half ...

Press release home snapshot 

Related Business 
Drug and Alcohol Treatment Centers (Popularity: ): Drug treatment is a valuable tool for people with a drug addiction that teaches them how to abstain from drug use and live a happily and a productive life. There are many ways to approach drug treatment.
OHTN - Ontario HIV Treatment Network (Popularity: ): A network of people living with HIV/AIDS, health care providers, researchers, local organizations and government policy relating to the care of people with HIV in Ontario. Drug benefits information, news, and job opportunities.
PCR Proven HIV Cure (Popularity: ): HIV/ Aids treatment for cure in south africa & uganda from HOOTONE REMEDIES. PCR Proven medicine reducing the possibility of developing resistance to any one drug class. Anti-HIV drugs tend to have more than one name. These drugs target an HIV protein called Hootone Remedies. The same test was repeated for 2nd, 3rd 4th year after completely stopping the medications and the patients yet recorded 'Not Detected' for the test ...
Colorado Drug Treatment Centers (Popularity: ): Drug Rehab Colorado can provide you with all your drug rehab and treatment options that best fits your specific situation and treatment needs. Drug Rehab Colorado counselors have tremendous knowlege and experience in assessing your specific treatment needs and we utilize an extensive Colorado Drug Rehab database containing Colorado drug and/or alcohol rehabs and treatment programs.
HIV Drug Interactions (Popularity: ): Laboratory and clinical findings relating to potential drug interactions between medications used to treat HIV infection. Universtity of Liverpool maintains this site.
California Drug Treatment (Popularity: ): Pax House is the best treatment center of drug treatment in California. Pax house is the best drug and substance abuse rehab center. Our residential California drug treatment program is located in the serene foothills of Altadena, at a co-ed facility that offers various lengths of treatment (including in-patient and outpatient programs), based on the needs of each client. We are committed to supplying personalized treatment plans to fit the ...
Drug Rehab and Drug Addiction (Popularity: ): Guide to Learn About Drug Rehab. The best place for seek guidance, advices and useful tips around drug rehab and drug addiction, directly from the expert. Some of the drug user might need to take more than one kind of treatment to defeat their dependency to drug. The rest might be fortune to defeat their dependency only with one treatment but some did not succeed to stay off the drugs ...
Zadaxin (Popularity: ): Thymosin alpha 1 (thymalfasin), a treatment for chronic hepatitis B when used alone or in combination with interferon. (Note: Not FDA approved for use in USA)
Liver Treatment (Popularity: ): Harshul Ayur Pharma is the manufacturere of "Savliv Drops", a wonder drug used in the treatment of Liver Cirrhosis, Ascites, HIV/AIDS, Hepatitis, Jaundice and many other liver diseases.
Infant Botulism Treatment and Prevention Program (Popularity: ): Official sites for physicians to obtain BabyBIG, an FDA approved orphant drug for treatment of infant botulism type A and B. Also provides parent support forum and medical/clinical information on the disease.